Christine Landlinger-Schubert, PhD, OncoOne, Klosterneuburg, Austria, discusses the anti-oxMIF antibody ON203 or targeting solid tumors, which is currently in the preclinical stages of development. A first in-human Phase I dose-escalation study assessing the safety, tolerability and pharmacokinetics of ON203 in patients with solid tumors, including non-small cell lung cancer (NSCLC) is in preparation. Primary outcomes will include the number and severity of adverse events and secondary outcomes will explore pharmacokinetic parameters, tumor response, and time to progressive disease. Exploratory measures will look at levels of total MIF, oxMIF, and cancer cell DNA in circulation, along with development of anti-drug antibodies, and examination of immune cell contexture before and during treatment in tumor biopsies. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
